



**Aarey**

**DRUGS & PHARMACEUTICALS LTD.**

**MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**

GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 12<sup>th</sup> November, 2021

To,

**BSE Limited**  
The Manager,  
Corporate Service Department  
P.J. Towers, Dalal Street,  
Mumbai- 400 001

**Scrip Code: 524412**

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400051

**NSE Symbol: AAREYDRUGS**

**Sub: Outcome of Board Meeting held on today i.e 12th November, 2021**

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 10<sup>th</sup> August, 2021 have passed the following resolution.

1. The Board of Directors of the Company has considered and approved the Unaudited Financial Results for the half year ended 30<sup>th</sup> September, 2021 along with the Limited Review Report, Balancesheet, Cashflow, MD/CFO certification.


The meeting was started at 03:30p.m. and was concluded at 04:00p.m

Kindly take the same on record.

Thanking you,

Yours Faithfully,

**For AAREY DRUGS & PHARMACEUTICALS LIMITED**

  
Mihir R Ghatalia  
Managing Director  
DIN: 00581005





**Aarey**

**DRUGS & PHARMACEUTICALS LTD.**

**MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**

GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 12<sup>th</sup> November, 2021

<b>BSE Limited</b> The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001  <b>Scrip Code: 524412</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051  <b>NSE Symbol: AAREYDRUGS</b>
--	---

Sub: Unaudited Financial Results for the half year ended 30<sup>th</sup> September, 2021.

Dear Sir/Madam,

Pursuant to the Listing agreement we are enclosing herewith the Unaudited financial results for the half year ended 30<sup>th</sup> September, 2021 with Limited Review Report.

Please take on record of the same and oblige.

Thanking you,

Yours Faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

  
Mihir R Ghatalia  
Managing Director  
DIN: 00581005



Encl.: a/a



# Aarey

## DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

### STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF - YEAR ENDED SEPTEMBER 30, 2021

(Rs. in Lakhs excluding EPS)

Sr.No.	PARTICULARS	Quarter ended			Half - year ended		Year ended
		30-Sep-21 (Unaudited)	30-Jun-21 (Unaudited)	30-Sep-20 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-20 (Unaudited)	31-Mar-21 (Audited)
I)	Revenue from Operations	13,464.90	9,751.78	4,982.40	23,216.68	7,504.17	34,841.64
II)	Other Income	81.49	67.08	254.96	148.57	328.70	701.46
III)	<b>Total Income (I+II)</b>	<b>13,546.39</b>	<b>9,818.86</b>	<b>5,237.35</b>	<b>23,365.25</b>	<b>7,832.86</b>	<b>35,543.10</b>
IV)	<b>Expenses:</b>						
	Cost of Materials Consumed	13,428.22	8,452.69	5,367.55	21,880.91	7,526.35	33,925.48
	Changes in Inventories of Finished goods, Work in progress and Stock in trade	-495.75	837.56	(527.33)	341.81	(426.23)	(146.46)
	Employee Benefit Expenses	12.56	10.85	-	23.42	-	39.55
	General Administrative Expense	17.12	17.47	11.63	34.59	35.98	225.33
	Selling and Distribution Exp	106.35	111.37	66.95	217.73	88.16	333.86
	Depreciation and Amortization Expense	50.00	40.00	22.35	90.00	44.70	92.04
	Finance Cost	60.90	47.09	80.07	107.99	126.71	243.16
	Other Expenses	54.62	28.97	31.56	83.59	96.77	-
	<b>Total Expenses (IV)</b>	<b>13,234.03</b>	<b>9,546.00</b>	<b>5,052.78</b>	<b>22,780.03</b>	<b>7,492.44</b>	<b>34,712.96</b>
V)	<b>Profit (+) / Loss (-) before Exceptional and Tax (III-IV)</b>	<b>312.36</b>	<b>272.86</b>	<b>184.57</b>	<b>585.22</b>	<b>340.42</b>	<b>830.14</b>
VI)	Exceptional Items	-	-	-	-	-	-
VII)	<b>Profit (+) / Loss (-) before Tax (V-VI)</b>	<b>312.36</b>	<b>272.86</b>	<b>184.57</b>	<b>585.22</b>	<b>340.42</b>	<b>830.14</b>
VIII)	<b>Tax Expenses</b>						
	a) Current Tax	(28.00)	(22.00)	-	(50.00)	-	(166.40)
	b) Deferred Tax	-	-	-	-	-	(12.31)
IX)	<b>Profit (+) / Loss (-) for the period (VII-VIII)</b>	<b>284.36</b>	<b>250.86</b>	<b>184.57</b>	<b>535.22</b>	<b>340.42</b>	<b>651.43</b>
X)	<b>Other Comprehensive Income (OCI)</b>						
	i. Items that will not be reclassified to Profit and Loss	-	-	-	-	-	-
	ii. Income Tax relating to Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	iii. Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	iv. Income Tax relating to Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	<b>Total Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XI)	<b>Total Comprehensive Income for the period</b>	<b>284.36</b>	<b>250.86</b>	<b>184.57</b>	<b>535.22</b>	<b>340.42</b>	<b>651.43</b>
	<b>Earnings Per Share</b>						
	a) Basic EPS (Rs.)	1.22	1.07	0.79	2.29	1.46	2.79
	b) Diluted EPS (Rs.)	1.22	1.07	0.79	2.29	1.46	2.79
	Number of Shares	23,384,684	23,384,684	23,384,684	23,384,684	23,384,684	23,384,684
	Percentage of Shareholding	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	Paid up Equity Share Capital (Face Value of Rs.10/ each)	2,338.47	2,338.47	2,338.47	2,338.47	2,338.47	2,338.47

#### Notes :

- The above results are restated as per the applicable Indian Accounting Standard (Ind AS) and are approved by audit committee and taken
- Status of Investor Complaints (Nos) : Opening as on 01.07.2021 - Nil ; Received During the Quarter - Nil ; Disposed Off During the Quarter - Nil ; Closing Balance as on 30.09.2021 - Nil.
- The Figures of the previous year / period have been regrouped wherever necessary.

Place: Mumbai  
Date: 12th November, 2021

By order of the Board of Directors  
For Aarey Drugs & Pharmaceuticals Limited

(Mihir R Ghatalia)  
Managing Director  
DIN: 00581005



**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com**AAREY DRUGS & PHARMACEUTICALS LTD  
Statement of Assets and Liabilities as at September 30, 2021**

(Rs. In Lakhs)

Particulars	As at Sep 30, 2021	As at Mar 31, 2021
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	1,532.16	1,425.81
<b>Financial Assets</b>		
Investments	383.05	40.00
Other Financial Assets	-	-
Deferred Tax Assets	-	-
<b>Other Non Current Assets</b>	-	-
<b>Total Non-current assets</b>	<b>1,915.21</b>	<b>1,465.81</b>
<b>Current assets</b>		
Inventories	1,504.26	1,846.06
<b>Financial Assets</b>		
Trade Receivables	18,850.30	16,201.23
Cash and Cash Equivalents	10.50	63.67
Other Bank Balances	1.21	1.30
Loans & Advances	2.00	2.00
Other Financial Assets	671.69	649.35
<b>Income Tax Assets (net)</b>	-	-
<b>Other Current Assets</b>	<b>3,413.86</b>	<b>3,074.13</b>
<b>Total current assets</b>	<b>24,453.81</b>	<b>21,837.75</b>
<b>Total assets</b>	<b>26,369.02</b>	<b>23,303.57</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	2,338.47	2,338.47
Other Equity	8,082.80	7,547.58
<b>Total Equity</b>	<b>10,421.27</b>	<b>9,886.05</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
<b>Financial Liabilities</b>		
Deferred Tax Liabilities	156.32	156.32
Other Non Current Liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>156.32</b>	<b>156.32</b>
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
Borrowings	2,262.66	1,801.72
Trade Payables	13,046.74	11,033.99
Other Financial Liabilities	129.85	65.61
Provisions	341.00	347.20
Other Current Liabilities	11.18	12.68
<b>Total Current Liabilities</b>	<b>15,791.43</b>	<b>13,261.20</b>
<b>Total Equity and Liabilities</b>	<b>26,369.02</b>	<b>23,303.57</b>

By order of the Board of Directors  
For Aarey Drugs & Pharmaceuticals Limited  
(Mihir R Ghatalla)  
Managing Director  
DIN: 00581005Place: Mumbai  
Date: 12th November, 2021

**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.comAarey Drugs & Pharmaceuticals Limited  
CIN: L99999MH1990PLC056538  
Cash Flow Statement for the Half year ended September 30, 2021

(Rs. In Lakhs)

Particulars	For the half - year	
	ended Sep 30, 2021	ended Sep 30, 2020
<b>Operating activities</b>		
Profit Before Tax	585.22	340.43
<b>Adjustments to reconcile profit before tax to net cash inflow</b>		
Depreciation and amortisation	90.00	44.70
Right Issue	-	-
Finance Cost	107.99	126.71
	783.21	511.84
<b>Working capital adjustments :-</b>		
(Increase) / Decrease in Trade and Other Receivables	(2,649.07)	2,337.90
(Increase) / Decrease in Inventories	341.80	(426.23)
(Increase) / Decrease in Loan & Advances	-	-
(Increase) / Decrease in Investments	(343.05)	-
(Increase) / Decrease in Other Current Financial Assets	(22.34)	(329.12)
Increase / (Decrease) in Provisions	(6.20)	-
Increase / (Decrease) in Trade and Other Payables	2,012.75	(7,320.38)
Increase / (Decrease) in Other Financial Liabilities	64.24	-
Increase / (Decrease) in Short term Borrowings	460.94	-
Increase / (Decrease) in other Current Liabilities	(1.50)	64.45
(Increase) / Decrease in Other Current assets	(339.73)	5,790.70
<b>Cash generated from operations</b>	<b>301.06</b>	<b>629.16</b>
Direct taxes paid (Net off Refund)	50.00	-
<b>Net cash flow from operating activities</b>	<b>251.06</b>	<b>629.16</b>
<b>Investing activities</b>		
Purchase of Property, Plant and Equipment	(196.33)	(42.00)
Interest received	-	-
<b>Net cash flow used in investing activities</b>	<b>(196.33)</b>	<b>(42.00)</b>
<b>Financing activities</b>		
Repayment/received of long term & advance	-	(450.92)
Finance cost	(107.99)	(126.71)
<b>Net cash flow from financing activities</b>	<b>(107.99)</b>	<b>(577.63)</b>
<b>Increase in cash and cash equivalents</b>	<b>(53.26)</b>	<b>9.53</b>
Cash and cash equivalents at the beginning of the year	64.97	50.27
Cash and cash equivalents at the end of the year	11.71	59.80

By order of the Board of Directors  
For Aarey Drugs & Pharmaceuticals Limited(M)hir R Ghatalia  
Managing Director  
DIN: 00581005Place: Mumbai  
Date: 12/11/2021



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

To,  
The Board of Directors  
Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter and half - year ended September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with Circular No. SEBI/HO/DDHS/CIR/2021/0000000638 dated 14th October 2021 ("the Circular").
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Motilal & Associates LLP**  
(Formerly Known As Motilal & Associates)

**Chartered Accountants**

ICAI FRN: 106584W/W100751

**CA RISHABH M JAIN**

Partner

Mem. No. : 179547



Place : Mumbai

Date : 12/11/2021

**UDIN: 21179547AAAACK2620**

## Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the half year ended 30<sup>th</sup> September, 2021 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mihir R. Ghatalia

MD

Date: 12/11/2021

Place: Mumbai

## **Certificate of Chief Financial Officer (CFO)**

I, Mira R. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the half year ended 30<sup>th</sup> September, 2021 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mira R.. Ghatalia

CFO

Date:12/11/2021

Place: Mumbai